Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Life Sciences
Treatment Of Late Stage Disease In A Model Of Arenaviral Hemorrhagic Fever: T-705 Efficacy And Reduced Toxicity Suggests An Alternative To Ribavirin, B B. Gowen, D F. Smee, M H. Wong, J O. Hall, K H. Jung, K W. Bailey, J R. Stevens, Y Furuta, John D. Morrey
Treatment Of Late Stage Disease In A Model Of Arenaviral Hemorrhagic Fever: T-705 Efficacy And Reduced Toxicity Suggests An Alternative To Ribavirin, B B. Gowen, D F. Smee, M H. Wong, J O. Hall, K H. Jung, K W. Bailey, J R. Stevens, Y Furuta, John D. Morrey
John D. Morrey
A growing number of arenaviruses are known to cause viral hemorrhagic fever (HF), a severe and life-threatening syndrome characterized by fever, malaise, and increased vascular permeability. Ribavirin, the only licensed antiviral indicated for the treatment of certain arenaviral HFs, has had mixed success and significant toxicity. Since severe arenaviral infections initially do not present with distinguishing symptoms and are difficult to clinically diagnose at early stages, it is of utmost importance to identify antiviral therapies effective at later stages of infection. We have previously reported that T-705, a substituted pyrazine derivative currently under development as an anti-influenza drug, is highly …